Waters (WAT) is in focus after launching its BioResolve Peptide and GTxResolve Lipid columns and securing FDA 510(k) clearance for the BD BACTEC FXI Culture System, developments that expand its biopharma and diagnostics footprint.

Despite the product launches and diagnostics clearance, Waters’ share price shows mixed momentum, with a 30 day share price return of 9.51% and a 90 day share price return of 22.20%, while the 1 year total shareholder return sits at 5.70%.

If you are interested in other lab and biopharma related opportunities, it could be worth scanning the market for companies connected to analytical tools and drug development using the 20 top founder-led companies

With Waters stock up over the past quarter and trading at a discount to both analyst targets and some intrinsic estimates, investors now face a key question: is there still value on the table, or has the market already priced in future growth?

Most Popular Narrative: 8.3% Undervalued

Waters closed at $360.54 compared with a widely followed narrative fair value of $393.14, which frames the current debate around how much future growth is already reflected in the share price.

Waters is poised to benefit from robust growth in pharmaceutical R&D, evidenced by strong double-digit pharma segment expansion, increased instrument replacement cycles, and deeper penetration into high-growth areas like CDMOs and generics, and this supports sustained revenue growth and pricing power as new product launches gain traction.

Want to understand why this valuation leans above today’s price? The narrative leans on fast compounding revenues, shifting margins, and a premium earnings multiple that assumes meaningful execution.

Result: Fair Value of $393.14 (UNDERVALUED)

However, Waters’ narrative could be tested if the planned BD combination delivers lower-than-modeled cost and revenue synergies, or if academic and government demand remains weak.

Another View: What Multiples Say About Waters Stock

The narrative and intrinsic estimates point to upside for Waters, but the current P/E of 78.7x paints a stricter picture. It is far above the company’s own fair ratio of 30.3x, the Global Life Sciences industry average of 35x, and the peer average of 29.8x, which suggests meaningful valuation risk if sentiment cools.

For a closer look at how these earnings-based comparisons stack up, including where the P/E could gravitate toward over time, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mixed signals around Waters have you on the fence, it makes sense to review the details yourself and quickly weigh both sides. To see how the balance of concerns and potential upsides compares, review the 2 key rewards and 3 important warning signs

Looking for more stock ideas beyond Waters?

If Waters stock has your attention, do not stop here. Broader market ideas can help you compare quality, risk, and income potential side by side.

• Target resilient companies that aim to protect your capital in tougher periods by scanning 68 resilient stocks with low risk scores.
• Hunt for quality businesses priced below many expectations with our focused list in the 44 high quality undervalued stocks.
• Build a potential income stream for the long haul by checking companies in the 9 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.